Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review

References

• VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• CelliBRMacNeeWATS/ERS Task ForceStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
   PubMed Web of Science ®Google Scholar
• [No authors listed]In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study GroupChest19941055141114198181328
   PubMed Web of Science ®Google Scholar
• BenayounSErnstPSuissaSThe impact of combined inhaled bronchodilator therapy in the treatment of COPDChest20011191859211157588
   PubMed Web of Science ®Google Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med2008102111511152018804362
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensECombining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptomsRespir Med20101047995100420303247
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117
   PubMed Web of Science ®Google Scholar
• DonaldsonGCWilkinsonTMHurstJRPereraWRWedzichaJAExacerbations and time spent outdoors in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2005171544645215579723
   PubMed Web of Science ®Google Scholar
• PittaFTroostersTProbstVSSpruitMADecramerMGosselinkRPhysical activity and hospitalization for exacerbation of COPDChest2006129353654416537849
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJMartínez-GarcíaMARomán SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• KannerREAnthonisenNRConnettJELung Health Study Research GroupLower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health studyAm J Respir Crit Care Med2001164335836411500333
   PubMed Web of Science ®Google Scholar
• LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationJ Clin Epidemiol20096210e1e3419631507
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementBMJ2009339b253519622551
   PubMed Web of Science ®Google Scholar
• Van de MaeleBFabbriLMMartinCHortonRDolkerMOverendTCardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patientsCOPD20107641842721166630
   PubMedGoogle Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• DahlRJadayelDAlagappanVKChenHBanerjiDEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyInt J Chron Obstruct Pulmon Dis2013850150824159259
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE studyEur Respir J Epub10312013
   Web of Science ®Google Scholar
• MahlerDAWitekTJJrThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
   PubMedGoogle Scholar
• van NoordJABuhlRLaforceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax201065121086109120978028
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• BeehKMKornSBeierJEffect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT studyRespir Med Epub1212014
   Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDINTRUST-1 and INTRUST-2 study investigatorsConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax201267978178822544891
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• BertonDCReisMSiqueiraACEffects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPDRespir Med201010491288129620580216
   PubMed Web of Science ®Google Scholar
• TashkinDPPearleJIezzoniDVargheseSTFormoterol and tiotropium compared with tiotropium alone for treatment of COPDCOPD200961172519229704
   PubMedGoogle Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in copd: a randomized, controlled studyChest Epub122014
   Web of Science ®Google Scholar
• Domínguez-FandosDFerrerEPuig-PeyREffects of aclidinium bromide in a cigarette smoke-exposed Guinea pig model of chronic obstructive pulmonary diseaseAm J Respir Cell Mol Biol201450233734624032416
   PubMed Web of Science ®Google Scholar
• JohnsonMRennardSAlternative mechanisms for long-acting beta(2)-adrenergic agonists in COPDChest2001120125827011451847
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMSeemungalTAThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J20124061545155422835613
   PubMed Web of Science ®Google Scholar